Bupropion Hydrochloride; Naltrexone Hydrochloride Patent Expiration
Bupropion Hydrochloride; Naltrexone Hydrochloride is used for chronic weight management and treating overweight or obesity, as well as to address blood glucose parameters and major depressive disorder in patients. It was first introduced by Nalpropion Pharmaceuticals Llc
Bupropion Hydrochloride; Naltrexone Hydrochloride Patents
Given below is the list of patents protecting Bupropion Hydrochloride; Naltrexone Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Contrave | US10231964 | Compositions and methods for weight loss in at risk patient populations | Jul 02, 2034 | Nalpropion |
| Contrave | US10828294 | Compositions and methods for weight loss in at risk patient populations | Jul 02, 2034 | Nalpropion |
| Contrave | US10835527 | Compositions and methods for reducing major adverse cardiovascular events | Jul 02, 2034 | Nalpropion |
| Contrave | US11998542 | Compositions and methods for reducing major adverse cardiovascular events | Jul 02, 2034 | Nalpropion |
| Contrave | US9633575 | Methods of treating overweight and obesity | Jun 25, 2033 | Nalpropion |
| Contrave | US10403170 | Methods of treating overweight and obesity | Jun 05, 2033 | Nalpropion |
| Contrave | US11139056 | Methods of treating overweight and obesity | Jun 05, 2033 | Nalpropion |
| Contrave | US9248123 | Methods of providing weight loss therapy in patients with major depression | Jan 13, 2032 | Nalpropion |
| Contrave | US11033543 | Methods of providing weight loss therapy in patients with major depression | Jan 10, 2031 | Nalpropion |
| Contrave | US8916195 | Sustained release formulation of naltrexone | Feb 02, 2030 | Nalpropion |
| Contrave | US11324741 | Methods for treating visceral fat conditions | May 29, 2029 | Nalpropion |
| Contrave | US8088786 | Layered pharmaceutical formulations | Feb 03, 2029 | Nalpropion |
| Contrave | US10307376 | Methods for administering weight loss medications | Nov 08, 2027 | Nalpropion |
| Contrave | US12048769 | Methods for administering weight loss medications | Nov 08, 2027 | Nalpropion |
| Contrave | US8318788 | Layered pharmaceutical formulations | Nov 08, 2027 | Nalpropion |
| Contrave | US8722085 | Methods for administering weight loss medications | Nov 08, 2027 | Nalpropion |
| Contrave | US9125868 | Methods for administering weight loss medications | Nov 08, 2027 | Nalpropion |
| Contrave | US9107837 | Sustained release formulation of naltrexone | Jun 04, 2027 | Nalpropion |
| Contrave | US7375111 | Compositions for affecting weight loss | Mar 26, 2025 | Nalpropion |
| Contrave | US7462626 | Compositions for affecting weight loss |
Jul 20, 2024
(Expired) | Nalpropion |
| Contrave | US8815889 | Compositions and methods for increasing insulin sensitivity |
Jul 20, 2024
(Expired) | Nalpropion |
| Contrave | US11278544 | Compositions for affecting weight loss |
Apr 21, 2024
(Expired) | Nalpropion |
Bupropion Hydrochloride; Naltrexone Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List